2024-06-27 04:13:22 ET
Summary
- ALX Oncology valuation has dropped below $500 million, presenting new studies at venues like ASCO, reaching a point of inflection.
- Evorpacept is the main focus, showing promising activity signals in gastric cancer and urothelial carcinoma, with upcoming data updates and trials.
- Financially, ALXO has a reasonable cash pool to fund operations for the near term, with a runway of 5-6 quarters.
Topline Summary and Update
Read the full article on Seeking Alpha
For further details see:
ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation